Device choice has long been a driver of sales of certain inhaled therapies, especially those available in multiple inhalers. With generic LAMAs and LABA/ICS FDCs anticipated to launch in the United States, devices may become an even more important driver of physician choice among respiratory therapies. Surveyed and interviewed practitioners note that while insurance often constrains their prescribing options, the device used with a therapy is an important driver and will become even more important as generic drug/device combinations become available. Unmet needs in the device market remain, especially for simpler devices and improved lung deposition.

Questions Answered:

  • What are the treatment drivers and goals for asthma and COPD?
  • What drug/device attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current drug/device combinations perform on key treatment drivers and goals for asthma and COPD?
  • What are the prevailing areas of unmet need and opportunity in drug/device combinations for asthma and COPD?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. pulmonologists for a hypothetical new drug/device combination for asthma and COPD?

Markets covered: United States

Primary research: Survey of 60 U.S. pulmonologists fielded in March 2017

Key companies: GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, Teva, Mylan, Propeller Health

Key drugs: Spiriva HandiHaler, Spiriva Respimat, Anoro Ellipta, Brovana, Symbicort HFA, Advair HFA, Advair Diskus

Table of contents

  • Special Topics: Devices (US)
    • Introduction
      • Overview
      • Key Findings
    • Current Devices and Clinical Practice
      • Current Device Training and Selection
      • Currently Available Drug/Device Combinations
    • Treatment Drivers and Goals
      • Overview
      • Treatment Drivers and Goals
        • Methodology
        • Physician Weighting of Clinical and Nonclinical Attributes
      • Rationale for Treatment Drivers and Goals Selection
        • Clinical Factors
        • Device Features
        • Device/Molecule Franchise
        • Patient-Related Factors
      • Physician Rating of Treatment Drivers and Goals in Asthma and COPD
        • Clinical Factors
        • Device Features
        • Device and Molecule Franchise
        • Patient-Related Factors
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Drug/Device Profiles
        • Spiriva HandiHaler
        • Spiriva Respimat
        • Anoro Ellipta
        • Brovana Nebulizer
        • Symbicort HFA
        • Advair HFA
        • Advair Diskus
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Clinical Factors
        • Device Features
        • Device and Molecule Franchise
        • Patient-Related Factors
    • Target Product Profiles
      • Stated vs. Derived Importance of Treatment Drivers and Goals
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • Asthma and COPD Devices Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Generic LABA/ICS FDCs Competing with Branded Versions
        • Emerging Triple Therapies Competing with Current Market Leaders
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment Drug/Device Combinations
      • Physician Rating of Unmet Need in Asthma and COPD Devices
        • Clinical Factors
        • Device Features
        • Device and Molecule Franchise
        • Patient-Related Factors
      • Unmet Need in Asthma and COPD Devices
    • Opportunity Analysis
      • Areas of Opportunity in the Asthma and COPD Drug/Device Market and Emerging Therapy Insights
        • Opportunity: Smart Devices
        • Opportunity: Generic Inhaled Therapies
        • Opportunity: Nebulized Therapies
    • Appendix
      • Experts Interviewed
      • Bibliography

Author(s): Kristine Mackin, PhD

Kristine Mackin, is an analyst on the immune and inflammatory disorders team at Decision Resources Group. She currently focuses on respiratory diseases, including asthma and COPD. She holds a doctorate in biochemistry from Brandeis University, where she studied the evolution of bacteriorhodopsin and the relationship between type I and type II rhodopsins. During her in Chemistry at Carleton College, she researched proinsulin processing. Prior to joining DRG, Dr. Mackin was involved with literature and market research for a new company pitch during an internship at Puretech Ventures in Boston, MA.


Related Reports

Asthma | Emerging Therapies | Dupixent (Dupilumab) (US) Wave 3

Dupixent (Sanofi / Regeneron), a first-in-class biologic that inhibits IL-4 / IL-13 signaling, was approved for the treatment of...

View Details

Asthma | Landscape & Forecast | Disease Landscape & Forecast

The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim&rsquo...

View Details

Asthma | Emerging Therapies | Asthma & COPD | Salmeterol & Fluticasone Generic Wave 2 (US)

Mylan’s salmeterol / fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK’s Advair, one of the top-selling the...

View Details

Chronic Obstructive Pulmonary Disease | Emerging Therapies | Asthma & COPD | Salmeterol & Fluticasone Generic Wave 2 (US)

Mylan’s salmeterol / fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK’s Advair, one of the top-selling the...

View Details